{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:35:20Z","timestamp":1790717720958,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Kidney transplantation is the therapeutic of choice for patients with kidney failure. While immunosuppressive drugs can control graft rejection, their use is associated with increased infections and cancer, and they do not effectively control chronic graft rejection. Cell therapy is an attractive strategy to minimize the use of pharmacological drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We recently developed a protocol to generate human monocyte-derived autologous tolerogenic dendritic cells (ATDCs) from healthy volunteers. Herein, we transferred the ATDC manufacturing protocol to a Good Manufacturing Practice (GMP)\u2013compliant facility. Furthermore, we compared the phenotype and in vitro functions of ATDCs generated from patients with end-stage renal disease to those generated from healthy volunteers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>We describe the critical steps for GMP-compliant production of ATDCs and define the quality criteria required to allow release of the cell products. Furthermore, we showed that ATDCs generated from healthy volunteers and patients with kidney failure display the same tolerogenic profile based on their phenotype, resistance to maturation, and ability to modulate T-cell responses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Together, these results allowed us to define the production process and the quality criteria for the release of ATDCs before their administration in patients receiving a kidney transplant.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003315","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:29:04Z","timestamp":1590010144000},"page":"832-841","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Preclinical Assessment of Autologous Tolerogenic Dendritic Cells From End-stage Renal Disease Patients"],"prefix":"10.1097","volume":"105","author":[{"given":"Laurence","family":"Bouchet-Delbos","sequence":"first","affiliation":[{"name":"INSERM, CHU Nantes, Nantes Universit\u00e9, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Even","sequence":"additional","affiliation":[{"name":"INSERM, CHU Nantes, Nantes Universit\u00e9, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Varey","sequence":"additional","affiliation":[{"name":"INSERM, CHU Nantes, Nantes Universit\u00e9, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Sa\u00efagh","sequence":"additional","affiliation":[{"name":"CHU Nantes, Unit\u00e9 de Therapie Cellulaire et Genique, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Bercegeay","sequence":"additional","affiliation":[{"name":"CHU Nantes, Unit\u00e9 de Therapie Cellulaire et Genique, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Braudeau","sequence":"additional","affiliation":[{"name":"INSERM, CHU Nantes, Nantes Universit\u00e9, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France."},{"name":"CHU Nantes, Nantes Universit\u00e9, Laboratoire d\u2019Immunologie, CIMNA, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[{"name":"CHU Nantes, Unit\u00e9 de Therapie Cellulaire et Genique, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Blancho","sequence":"additional","affiliation":[{"name":"INSERM, CHU Nantes, Nantes Universit\u00e9, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Josien","sequence":"additional","affiliation":[{"name":"INSERM, CHU Nantes, Nantes Universit\u00e9, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France."},{"name":"CHU Nantes, Nantes Universit\u00e9, Laboratoire d\u2019Immunologie, CIMNA, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Cristina","family":"Cuturi","sequence":"additional","affiliation":[{"name":"INSERM, CHU Nantes, Nantes Universit\u00e9, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France."},{"name":"LabEx IGO (Immunotherapy, Graft, Oncology), Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Moreau","sequence":"additional","affiliation":[{"name":"INSERM, CHU Nantes, Nantes Universit\u00e9, Centre de Recherche en Transplantation et Immunologie UMR1064, ITUN, Nantes, France."},{"name":"LabEx IGO (Immunotherapy, Graft, Oncology), Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2018.00274","article-title":"Tolerogenic dendritic cells in solid organ transplantation: where do we stand?","volume":"9","author":"Mar\u00edn","year":"2018","journal-title":"Front Immunol"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8","article-title":"Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo.","volume":"30","author":"Lutz","year":"2000","journal-title":"Eur J Immunol"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.4049\/jimmunol.178.11.7018","article-title":"Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance.","volume":"178","author":"Turnquist","year":"2007","journal-title":"J Immunol"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.4049\/jimmunol.177.9.5868","article-title":"\u201cAlternatively activated\u201d dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig.","volume":"177","author":"Lan","year":"2006","journal-title":"J Immunol"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.4049\/jimmunol.1401423","article-title":"Combining autologous dendritic cell therapy with CD3 antibodies promotes regulatory T cells and permanent islet allograft acceptance.","volume":"193","author":"Baas","year":"2014","journal-title":"J Immunol"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/01.TP.0000158277.50073.35","article-title":"Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression.","volume":"79","author":"B\u00e9riou","year":"2005","journal-title":"Transplantation"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-6143.2004.00683.x","article-title":"Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors.","volume":"5","author":"P\u00eache","year":"2005","journal-title":"Am J Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/ajt.12708","article-title":"Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation.","volume":"14","author":"Segovia","year":"2014","journal-title":"Am J Transplant"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/j.1600-6143.2011.03651.x","article-title":"Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and Epstein-Barr virus-induced gene 3.","volume":"11","author":"Hill","year":"2011","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"290ra87","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients.","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/ecco-jcc\/jjv144","article-title":"Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn\u2019s Disease: a phase I study.","volume":"9","author":"Jauregui-Amezaga","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/ajt.12310","article-title":"Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates.","volume":"13","author":"Ezzelarab","year":"2013","journal-title":"Am J Transplant"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41467-018-05167-8","article-title":"TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity.","volume":"9","author":"Riquelme","year":"2018","journal-title":"Nat Commun"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/TP.0b013e31816f22d6","article-title":"Superiority of bone marrow-derived dendritic cells over monocyte-derived ones for the expansion of regulatory T cells in the macaque.","volume":"85","author":"Moreau","year":"2008","journal-title":"Transplantation"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1096\/fj.08-128173","article-title":"Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates.","volume":"23","author":"Moreau","year":"2009","journal-title":"Faseb J"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"14028","DOI":"10.1038\/mtm.2014.28","article-title":"Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer.","volume":"1","author":"Moreau","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2047-1440-1-11","article-title":"The ONE Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells.","volume":"1","author":"Geissler","year":"2012","journal-title":"Transplant Res"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1136\/ard.2009.126383","article-title":"Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis.","volume":"69","author":"Harry","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/eji.201141835","article-title":"Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients.","volume":"42","author":"Ra\u03cach-Regu\u00e9","year":"2012","journal-title":"Eur J Immunol"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4049\/jimmunol.1600676","article-title":"Tolerogenic dendritic cells from poorly compensated type 1 diabetes patients have decreased ability to induce stable antigen-specific T cell hyporesponsiveness and generation of suppressive regulatory T cells.","volume":"198","author":"D\u00e1\u0148ov\u00e1","year":"2017","journal-title":"J Immunol"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"13964","DOI":"10.1038\/s41598-018-31889-2","article-title":"Hemodialysis-related changes in phenotypical features of monocytes.","volume":"8","author":"Liakopoulos","year":"2018","journal-title":"Sci Rep"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.krcp.2013.08.001","article-title":"Proinflammatory CD14(+)CD16(+) monocytes are associated with vascular stiffness in predialysis patients with chronic kidney disease.","volume":"32","author":"Lee","year":"2013","journal-title":"Kidney Res Clin Pract"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"e2300","DOI":"10.7717\/peerj.2300","article-title":"Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies.","volume":"4","author":"Lord","year":"2016","journal-title":"PeerJ"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000279442","article-title":"Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition.","volume":"127","author":"Brothman","year":"2009","journal-title":"Cytogenet Genome Res"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cmet.2019.11.011","article-title":"Human tolerogenic dendritic cells regulate immune responses through lactate synthesis.","volume":"30","author":"Marin","year":"2019","journal-title":"Cell Metab"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.193.2.233","article-title":"Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.","volume":"193","author":"Dhodapkar","year":"2001","journal-title":"J Exp Med"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/ajt.14280","article-title":"Pretransplant numbers of CD16+ monocytes as a novel biomarker to predict acute rejection after kidney transplantation: a pilot study.","volume":"17","author":"van den Bosch","year":"2017","journal-title":"Am J Transplant"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2004-10-3927","article-title":"Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells.","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:14:40Z","timestamp":1749064480000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003315","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}